2025 A Focus on Cellular Therapies, T Cell Engagers and TIL Therapies

aci-cellular-therapies_-_Edited.png

friday, june 27, 2025 |11 a.m.–3 P.M. ET
live via zoom webinar

Register Now


Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of cellular therapies, T cell engagers and TIL Therapies. FREE for healthcare professionals, students, patients and patient advocates. 

New for 2025

  • View presentations on recent studies and approvals of cellular therapies for solid tumors, including TCR-engineered T cells and CAR T cells for pediatric brain malignancies.
  • Cover clinical trials and future directions of the newly approved DLL-targeting T cell engager for lung cancer.

  • Explore current cellular therapies options, including TILs for immune checkpoint inhibitor-resistant melanoma.

Program Organizers

Jason Luke, MD, FACP

Jason Luke, MD, FACP
UPMC Hillman Cancer Center

Robbie Majzner, MD

Robbie Majzner, MD
Dana-Farber Cancer Institute

Lei Zheng, MD, PhD

Lei Zheng, MD, PhD 
Johns Hopkins University

Program Snapshot

Credits Available
Physician Education: 3.75 AMA PRA Category 1TM
Pharmacy Education: 3.75 contact hours (0.375 CEUs)
Nursing Education: 3.75 contact hours

Program Date & Location

Friday, June 27, 2025 at 11 a.m.–3 p.m. ET
Live via Zoom Webinar

Program Cost

FREE for healthcare professionals, students, patients and patient advocates.

Register for A Focus on Cellular Therapies, T Cell Engagers & TIL Therapies >

Program Agenda

11–11:05 a.m.

 

Welcome

11:0511:35 a.m.

  TCR-Engineered T Cells for Solid Tumors

11:35 a.m.12:05 p.m.

 

CAR T Cells for Pediatric Brain Tumors  

12:0512:35 p.m.

 

T Cell Engagers: DLL3 in Small Cell Lung Cancer and Beyond 

12:35–1:05 p.m.

 

CARs vs. BiTEs for Hematological Malignancies

1:00–1:20 p.m.

 

Break 

1:20–2 p.m.

 

Cancer Immunotherapy in Practice: Approaching ICI-Resistant Melanoma (TILs, TCR T Cells) 

2–3 p.m.

 

Faculty Panel

3 p.m

 

Closing Remarks

    SITC ACI Series

    This program is part of the SITC ACI series. View below to explore more programs in the 2025 ACI series.

    Program Details

    Target Audience

    The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

    Case Study Submission Information

    As part of the program, registrants are encouraged to submit case studies for expert review during the case study panel concluding the program. If you are interested in taking advantage of this opportunity, please review and sign the linked case study guidelines, and return your case study and signed guidelines to education@sitcancer.org.

    Program Learning Objectives

    • Describe the mechanisms of T cell engagers and cellular therapies, including TIL therapies.
    • Summarize recent updates in the clinical use of T cell engagers and cell therapies, including the recent approvals of T cell engagers for solid tumors, TIL therapies, and TCR engineered T cells.
    • Outline common toxicities with T cell engagers and the different cell therapies and common approaches to managing these toxicities.
    • Identify unique institutional resources required for the appropriate use of cell therapies, including TIL therapy.

    Accreditation Information

    Joint Accreditation Statement

    thumbnail image In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and the Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)

    ABIM_Logo.jpgSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Physician Continuing Medical Education

    PACE designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Continuing Pharmacy Education

    PACE designates this continuing education activity for 3.75 contact hour(s) (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

    Continuing Nursing Education

    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 3.75 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

    Disclosures and ADA Info

    Disclosure of Conflicts of Interest

    PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

    Avoid Fraudulent ACI Websites

    Recently, the SITC office received communication about a fraudulent registration website for one of our ACI programs. To help ensure others don’t mistakenly register on an unauthorized, third-party website, we're proactively informing you to ensure you’re able to safely register for the event through the official SITC website, and so that you can confirm the communication you receive is truly from SITC.

    All official forthcoming ACI registration information will come from an email address ending in @sitcancer.org. If you have any questions, please contact the SITC office at events@sitcancer.org or 414-271-2456.

    The 2025 ACI series is jointly provided by Partners for Advancing Clinical Education and the Society for Immunotherapy of Cancer.